Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Eva Maria Wendel - , Klinikum Stuttgart (Autor:in)
  • Helen Sophie Thonke - , Universität Witten/Herdecke (Autor:in)
  • Annikki Bertolini - , Klinikum Stuttgart (Autor:in)
  • Matthias Baumann - , Medizinische Universität Innsbruck (Autor:in)
  • Astrid Blaschek - , Ludwig-Maximilians-Universität München (LMU) (Autor:in)
  • Andreas Merkenschlager - , Universität Leipzig (Autor:in)
  • Michael Karenfort - , Heinrich Heine Universität Düsseldorf (Autor:in)
  • Barbara Kornek - , Medizinische Universität Wien (Autor:in)
  • Christian Lechner - , Medizinische Universität Innsbruck (Autor:in)
  • Daniela Pohl - , University of Ottawa (Autor:in)
  • Martin Pritsch - , DRK-Kinderklinik Siegen gGmbH (Autor:in)
  • Kathrin Schanda - , Medizinische Universität Innsbruck (Autor:in)
  • Mareike Schimmel - , Universitätsklinikum Augsburg (Autor:in)
  • Charlotte Thiels - , Ruhr-Universität Bochum (Autor:in)
  • Stephan Waltz - , Kliniken der Stadt Köln gGmbH (Autor:in)
  • Gert Wiegand - , Asklepios Klinik St. Georg (Autor:in)
  • Banu Anlar - , Hacettepe University (Autor:in)
  • Nina Barisic - , University of Zagreb (Autor:in)
  • Christian Blank - , Kinderkrankenhaus St. Marien gGmbH, Universität Witten/Herdecke (Autor:in)
  • Markus Breu - , Medizinische Universität Wien (Autor:in)
  • Philip Broser - , Ostschweizer Kinderspital (Autor:in)
  • Adela Della Marina - , Universität Duisburg-Essen (Autor:in)
  • Katharina Diepold - , Hospital Kassel (Autor:in)
  • Matthias Eckenweiler - , Albert-Ludwigs-Universität Freiburg (Autor:in)
  • Astrid Eisenkölbl - , Kepler Universitätsklinikum (Autor:in)
  • Michael Freilinger - , Medizinische Universität Wien (Autor:in)
  • Ursula Gruber-Sedlmayr - , LKH-Universitätsklinikum Graz (Autor:in)
  • Annette Hackenberg - , Universität Zürich (Autor:in)
  • Tobias Iff - , Zentrum für Kinderneurologie AG (Autor:in)
  • Ellen Knierim - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Johannes Koch - , Paracelsus Medizinischen Privatuniversität (Autor:in)
  • Georg Kutschke - , Caritas-Krankenhaus Bad Mergentheim (Autor:in)
  • Steffen Leiz - , Klinikum Dritter Orden gGmbH (Autor:in)
  • Grischa Lischetzki - , Universität Hamburg (Autor:in)
  • Margherita Nosadini - , Azienda Ospedaliera di Padova (Autor:in)
  • Alexander Pschibul - , Albert-Ludwigs-Universität Freiburg (Autor:in)
  • Edith Reiter-Fink - , Medizinische Universität Wien, St. Anna Childrens` Hospital (Autor:in)
  • Doris Rohrbach - , Klinik Donaustadt (Autor:in)
  • Michela Salandin - , Hospital Bozen (Autor:in)
  • Stefano Sartori - , Fondazione Istituto di Ricerca Pediatrica Città della Speranza (Autor:in)
  • Jan Ulrich Schlump - , Medizinische Universität Innsbruck (Autor:in)
  • Johannes Stoffels - , KJF Klinikum Josefinum (Autor:in)
  • Jurgis Strautmanis - , Children's Clinical University Hospital (Autor:in)
  • Daniel Tibussek - , Asklepios Kinderklinik Sankt Augustin (Autor:in)
  • Victoria Tüngler - , Klinik und Poliklinik für Kinder- und Jugendmedizin, Abteilung für Neuropädiatrie (Autor:in)
  • Norbert Utzig - , Ernst-Moritz-Arndt-Universität Greifswald (Autor:in)
  • Markus Reindl - , Medizinische Universität Innsbruck (Autor:in)
  • Kevin Rostásy - , Universität Witten/Herdecke (Autor:in)

Abstract

BACKGROUND AND OBJECTIVE: The spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) comprises monophasic diseases such as acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), and transverse myelitis and relapsing courses of these presentations. Persistently high MOG antibodies (MOG immunoglobulin G [IgG]) are found in patients with a relapsing disease course. Prognostic factors to determine the clinical course of children with a first MOGAD are still lacking. The objective of the study is to assess the clinical and laboratory prognostic parameters for a risk of relapse and the temporal dynamics of MOG-IgG titers in children with MOGAD in correlation with clinical presentation and disease course.

METHODS: In this prospective multicenter hospital-based study, children with a first demyelinating attack and complete data set comprising clinical and radiologic findings, MOG-IgG titer at onset, and clinical and serologic follow-up data were included. Serum samples were analyzed by live cell-based assay, and a titer level of ≥1:160 was classified as MOG-IgG-positive.

RESULTS: One hundred sixteen children (f:m = 57:59) with MOGAD were included and initially diagnosed with ADEM (n = 59), unilateral ON (n = 12), bilateral ON (n = 16), myelitis (n = 6), neuromyelitis optica spectrum disorder (n = 8) or encephalitis (n = 6). The median follow-up time was 3 years in monophasic and 5 years in relapsing patients. There was no significant association between disease course and MOG-IgG titers at onset, sex, age at presentation, or clinical phenotype. Seroconversion to MOG-IgG-negative within 2 years of the initial event showed a significant risk reduction for a relapsing disease course. Forty-two/one hundred sixteen patients (monophasic n = 26, relapsing n = 16) had serial MOG-IgG testing in years 1 and 2 after the initial event. In contrast to relapsing patients, monophasic patients showed a significant decrease of MOG-IgG titers during the first and second years, often with seroconversion to negative titers. During the follow-up, MOG-IgG titers were persistently higher in relapsing than in monophasic patients. Decrease in MOG-IgG of ≥3 dilution steps after the first and second years was shown to be associated with a decreased risk of relapses. In our cohort, no patient experienced a relapse after seroconversion to MOG-IgG-negative.

DISCUSSION: In this study, patients with declining MOG-IgG titers, particularly those with seroconversion to MOG-IgG-negative, are shown to have a significantly reduced relapse risk.

Details

OriginalspracheEnglisch
Aufsatznummere200035
FachzeitschriftNeurology: Neuroimmunology & Neuroinflammation
Jahrgang9
Ausgabenummer6
PublikationsstatusVeröffentlicht - 13 Nov. 2022
Peer-Review-StatusJa

Externe IDs

PubMed 36229191
PubMedCentral PMC9562044
ORCID /0000-0003-3486-2824/work/151436586

Schlagworte

ASJC Scopus Sachgebiete

Schlagwörter

  • Encephalomyelitis, Acute Disseminated, Humans, Immunoglobulin G, Myelin-Oligodendrocyte Glycoprotein, Neoplasm Recurrence, Local, Neuromyelitis Optica, Optic Neuritis, Prospective Studies, Syndrome

Bibliotheksschlagworte